Tools chosen: polymarket_direct claude_news claude_news gdelt_news polymarket_related kalshi_related earnings_data wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Polymarket question about FDA approval of Moderna/Merck's intismeran autogene (mRNA-4157/V940) by end-2027. Key drivers are the Phase 3 INTerpath-001 readout timing, whether Moderna/Merck pursue accelerated approval based on Phase 2b KEYNOTE-942 data, BLA submission status, and FDA/political attitudes toward mRNA vaccines. I'll anchor on the Polymarket price, then research trial timelines, regulatory filings, and company guidance.

# Current state Phase 3 INTerpath-001 topline results were announced Aug 19, 2026 and were positive (met primary RFS and key secondary DMFS endpoints) — the first positive Phase 3 for an mRNA cancer vaccine. However, no BLA/sBLA has been filed; Merck/Moderna are still "engaging with regulators" and plan to present full data at a future medical conference. Approval requires this event (FDA approval letter) specifically, not just trial success — filing, review, and a decision must all occur before Dec 31, 2027, under an FDA leadership (CBER director Vinay Prasad) that has shown friction toward Moderna's mRNA platform. # Timeline of key events - 2023-02-22: FDA grants Breakthrough Therapy Designation to mRNA-4157/V940 + Keytruda for adjuvant high-risk melanoma (confirmed, Merck press release). - 2024 (date unspecified): Moderna/Merck hold preliminary talks with FDA about accelerated approval on Phase 2 data; FDA gives discouraging feedback (reported, BioSpace/FierceBiotech). - 2025-05: Vinay Prasad appointed CBER director; associated selloff in Moderna and other biotech stocks (confirmed appointment, reported market reaction). - 2026-02-13: CBER under Prasad issues a Refusal-to-File letter for Moderna's separate mRNA flu vaccine application (reported, Cancer Letter) — signals continued regulatory friction with Moderna's mRNA platform. - 2026-06-02/03: Media coverage of long-term (5-year) Phase 2 follow-up showing ~49% reduced recurrence (reported). - 2026-08-19: Phase 3 INTerpath-001 topline results announced — primary (RFS) and key secondary (DMFS) endpoints met at interim analysis; safety consistent with prior data (confirmed, Merck/Moderna joint release). - Post 2026-08-19: Companies state plan to present full data at an international medical meeting and "engage with regulators on filing submissions" — no BLA filing date, priority review designation, or PDUFA date announced as of research date (confirmed absence of filing). # Event Will the FDA approve intismeran autogene (mRNA-4157/V940, Moderna/Merck individualized neoantigen therapy) for any indication by Dec 31, 2027? # Outcomes to forecast Yes / No # Kalshi market anchor No direct Kalshi YES price was retrieved in this research pull (kalshi_direct tool did not return data). Best available anchor is Polymarket on the identical event: current YES 51% (down sharply from a 30-day high of 72.5%; -16.5% over 7 days, -21.5% over 30 days; volume ~$58.6k across 9 data points). The steep decline suggests the market is re-pricing downward despite the positive Aug 2026 trial readout, likely reflecting recognition that no BLA has been filed and regulatory/timeline risk is high. Related Kalshi FDA-approval markets (different drugs) trade 40-56% for similarly speculative multi-year windows (Verve-102 50%, MDMA/PTSD 56%, Type 1 diabetes cure 40%), providing rough category calibration but not drug-specific signal. # Sub-question answers 1. **Polymarket price/trend** — 51% currently, down from a peak of 72.5%; 30-day trend -21.5%, indicating recent bearish repricing despite positive trial news (polymarket_direct). 2. **Phase 3 readout timing/guidance** — Topline results already announced Aug 19, 2026 (interim analysis); trial continues for OS and other secondary endpoints; no specific BLA filing date given (claude_news/Merck). 3. **BLA plans / designation** — No BLA filed yet; companies say they will "engage with regulators on filing submissions." Program holds Breakthrough Therapy Designation since Feb 2023 (still active), which supports expedited review once filed (Merck, tipranks). 4. **FDA leadership posture** — CBER director Vinay Prasad is a known mRNA skeptic; FDA rebuffed a 2024 accelerated-approval bid and issued a 2026 Refusal-to-File for Moderna's separate mRNA flu vaccine, indicating elevated regulatory friction risk for Moderna mRNA products generally (biopharmadive, cancerletter). 5. **Historical base rate/lag** — No explicit precedent dataset was surfaced; Wikipedia notes standard accelerated-approval mechanics but no drug-specific lag data. Analyst commentary (code_execution model) treats priority review as 6-8 months from filing, but filing itself has not begun. 6. **Adverse events/trial or partnership issues** — No holds or enrollment delays reported; safety profile "consistent with previously reported studies, no new signals" (Merck 2026-08-19 release). No partnership/funding disruption reported between Merck and Moderna. # Key facts (high-confidence, factual) 1. [Merck/Moderna 2026-08-19] Phase 3 INTerpath-001 met primary (RFS) and key secondary (DMFS) endpoints at interim analysis; 1,137 patients enrolled. 2. [Merck 2023-02-22] Breakthrough Therapy Designation granted and remains active. 3. [BioSpace/FierceBiotech] FDA discouraged a 2024 accelerated-approval attempt based on Phase 2 data. 4. [BioPharma Dive/Cancer Letter] CBER director Vinay Prasad has an adversarial track record toward mRNA products, including a 2026 Refusal-to-File for Moderna's flu vaccine. 5. [Merck/Moderna] No BLA has been filed as of research date; only "plan to engage with regulators." # Cross-market signals - Kalshi related: Comparable FDA-approval markets price 40-56% for multi-year windows on unrelated drugs — not drug-specific, low signal value. - Polymarket: Same-event market at 51%, down sharply (-21.5% 30d) despite positive trial news — market pricing in filing/review timeline risk and regulatory friction. - Sportsbook implied: N/A. # Analyst opinions and speculation - Moderna President Stephen Hoge: positive interim data "would obviously make the case for an accelerated review" (FierceBiotech). - Secondary outlets (TravelersToday, SmartCancer) speculate approval "as early as 2027," citing expedited designations from FDA/EMA — explicitly labeled speculative, not company-confirmed. - code_execution decision-tree model (built partly on pre-readout assumptions) estimates ~10-15% base probability, driven mainly by uncertainty over filing/review timing fitting within the window. # Directional lean per outcome - **Yes**: Positive Phase 3 data now in hand, active Breakthrough Therapy Designation, sponsor rhetoric supportive of accelerated review, EMA/FDA expedited pathways cited. - **No**: No BLA filed yet (as of ~mid/late 2026), full dataset still pending conference presentation, only ~16 months remain to close, prior FDA rebuff (2024) and current CBER (Prasad) hostility toward Moderna mRNA products, HHS mRNA funding wind-down signaling broader skepticism, and Polymarket pricing has fallen sharply post-readout to 51%. # Gaps / unknowns - No confirmed BLA filing date or PDUFA date. - No official statement on whether sponsors will pursue accelerated approval or wait for full Phase 3 confirmatory data. - Kalshi's own direct price for this ticker was not retrieved in this research pass. - No visibility into any FDA advisory committee scheduling. # Calibration anchors - Polymarket (same event) YES: 51%, down from 72.5% peak — treat as closest available consensus anchor. - Prior FDA rejection of accelerated approval bid in 2024 for same drug is a strong negative precedent. - Analyst/model base-case estimate: ~10-15% (pre-dating full recognition of Aug 2026 positive readout, likely understating current probability somewhat, but tempered by no-BLA-yet status and CBER friction).

1. Both forecasters land below the Polymarket anchor (33% and 43% vs 51%) without fully justifying why they should diverge so far from the "closest available consensus anchor" they both cite — Forecast 1 in particular sits 18 points below the market with only qualitative reasoning, not a clear model for why the market is wrong rather than the forecasters being overconfident in downside scenarios. 2. Neither forecaster explicitly models the *manufacturing/CMC* risk highlighted in the brief for individualized neoantigen therapy (patient-specific vaccine manufacturing inspections are novel and could be a distinct approval bottleneck independent of clinical review timing) — this is mentioned only in passing by Forecast 1 and ignored by Forecast 2. 3. Both treat the 2024 accelerated-approval rebuff and the 2026 flu-vaccine Refusal-to-File as directly predictive of this program's fate, but neither considers that positive Phase 3 confirmatory data (not just Phase 2, as in 2024) fundamentally changes FDA's risk calculus — a full Phase 3 hit is a categorically stronger filing basis than what was rebuffed previously, so anchoring heavily on the 2024 precedent may overweight a stale analog. 4. Neither forecast seriously engages with the interim-analysis caveat: results were from an "interim analysis" with the trial continuing for OS and other endpoints, which could mean sponsors deliberately wait for more mature data before filing (further delaying BLA submission) — a scenario that pushes toward No more than either forecast's stated reasoning captures. 5. Both convert time pressure (16 months) into moderate-confidence No-leaning probabilities, but neither computes an explicit best-case timeline probability distribution (e.g., probability sponsors file by Q1 2027 AND get priority review AND no advisory committee delay) — the reasoning is narrative rather than decomposed, risking anchoring bias toward "sounds hard so lower than market." 6. Neither forecaster flags the polymarket volume caveat (~$58.6k across only 9 data points) as a reason to discount that anchor's reliability — the "51%" consensus could be thin/noisy, yet both forecasts treat it as a firm calibration point to deviate modestly from, rather than questioning its statistical robustness.

36% (62% confidence)

Yes: 36% No: 64%

The binding constraint is procedural, not clinical: as of the research date no BLA has been filed, full Phase 3 data is still awaiting conference presentation, and only ~16 months remain for submission, acceptance (2-month clock), priority review (~6 months), novel patient-specific CMC/manufacturing inspections, and a possible advisory committee — an aggressive-but-plausible path (file Q4 2026/Q1 2027) lands approval only in H2 2027 with little slack. The critique correctly notes that a positive Phase 3 is a categorically stronger filing basis than the 2024 Phase 2 accelerated-approval bid that FDA rebuffed, so I don't anchor heavily on that stale analog; but that upward adjustment is roughly offset by the interim-analysis caveat (sponsors may await maturer OS data) and by CBER-under-Prasad friction with Moderna's mRNA platform. The Polymarket 51% anchor is thin (~$58.6k, 9 data points) and falling sharply, so modest deviation below it is defensible rather than overconfident. Decomposing: ~60-65% chance of filing by roughly Q1 2027 times ~55-60% chance of an approval letter landing inside 2027 given such a filing yields ~35%, consistent with sitting between the two forecasts and below the noisy market.

Total pipeline time: 269.1s